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Several tolerance checkpoints exist throughout B cell development to control autoreactive B
cells and prevent the generation of pathogenic autoantibodies. FcγRIIb is an Fc receptor that
inhibits B cell activation and, if defective, is associated with autoimmune disease, yet its
impact on speciﬁc B cell tolerance checkpoints is unknown. Here we show that reduced
expression of FcγRIIb enhances the deletion and anergy of autoreactive immature B cells, but
in contrast promotes autoreactive B cell expansion in the germinal center and serum auto-
antibody production, even in response to exogenous, non-self antigens. Our data thus show
that FcγRIIb has opposing effects on pre-immune and post-immune tolerance checkpoints,
and suggest that B cell tolerance requires the control of bystander germinal center B cells
with low or no afﬁnity for the immunizing antigen.
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Three major tolerance checkpoints during B-cell develop-ment control the generation of autoreactive B-cell clones.The ﬁrst two checkpoints shape the pre-immune reper-
toire, while the third occurs following antigen-mediated activa-
tion1. First, the self-reactivity of immature B cells in the bone
marrow (BM) is tested, with a large fraction of autoreactive clones
being eliminated (a process called central tolerance)2–4. Auto-
reactive B cells that manage to leave the BM are subjected to
a second checkpoint as they transit from immature to mature
B cells in the blood and spleen, leading to a further decrease in
the frequency of autoreactive clones among mature B cells5,6.
Finally, following B-cell activation, autoreactive B cells may
also be eliminated from the germinal center or corrected
by somatic hypermutation, further reducing the chance of gen-
erating potentially harmful autoreactive memory B cells
and autoantibody-producing plasma cells. The last two check-
points, taking place outside the BM, contribute to peripheral
tolerance1,6,7.
At a cellular and molecular level, several mechanisms of B-cell
tolerance have been described. Clonal deletion and anergy were
ﬁrst proposed as major mechanisms regulating B-cell
tolerance2,3,5,8–10. Receptor editing has also been shown to play
a key role in central tolerance in the BM4,11,12. Autoreactive B
cells can also be excluded from the B-cell follicles, with a lack of T
cell help precipitating their subsequent apoptosis13,14. The nature
and location of speciﬁc autoantigens seem to determine which
tolerance mechanism is used, with deletion being preferentially
induced by high-avidity antigens while low-avidity interactions
tend to drive receptor editing and anergy9–11. Germinal center
(GC) tolerance mechanisms are still only partially characterised.
It has been suggested that autoantigens need to be present within
the germinal center to properly control autoreactive clones, either
by apoptosis15,16 or by redemption of their B-cell receptor (BCR)
via corrective somatic hypermutation7,17,18.
The strength of BCR signalling is thought to be important in all
of these mechanisms, suggesting that inhibitory receptors reg-
ulating the BCR threshold of activation may be central actors in
B-cell tolerance. The inhibitory receptor FcγRIIb negatively reg-
ulates signalling induced by the BCR19,20 and is involved in the
control of autoimmunity; however, its role in the regulation of
speciﬁc B-cell tolerance checkpoints has not been determined.
This question is important, as reduced FcγRIIB expression or
function has been associated with autoimmune disease in both
humans and mice. In humans, a single-nucleotide polymorphism
in FCGR2B leading to the replacement of an isoleucine by a
threonine at position 232 (T232I) results in reduced inhibitory
function21,22, and has been associated with susceptibility to
SLE23–27, but protection against malaria26,28. Humanised mice
reconstituted with cord blood cells bearing the 232T poly-
morphism display defective B-cell development and produce
autoantibodies29. Naturally occurring variations have also been
described in the promoter of human FCGR2B, and it has been
suggested these too may predispose to SLE30,31. FcγRIIb appears
to play a remarkably similar role in mouse and human biology.
Thus, FcγRIIb-deﬁcient mice present an exacerbated immune
response32,33, are prone to inducible and spontaneous auto-
immunity34–38 with more autoreactive GC B-cell clones39, and
are protected from malaria26. Transgenic mice overexpressing
FcγRIIb on B cells display a reverse phenotype, with reduced
immune responses and resistance to autoimmune disease40.
Interestingly, natural variants common in wild mice from the
Mus musculus genus have also been reported in the promoter
region of Fcgr2b41, and have been shown to be associated with
autoimmunity-prone laboratory strains42,43. By generating a
knock-in (KI) mouse model bearing these wild promoter variants
on the C57BL/6 background (FcγRIIbwild/H1 KI), we
demonstrated that they control the upregulation of FcγRIIb on B
cells upon activation. In the absence of FcγRIIb upregulation on
GC B cells, we observed an increased number of total GC B cells
following T-dependent immunisation, but, surprisingly, the
number of those speciﬁc for the immunising antigen was nor-
mal44. This suggested that FcγRIIb upregulation may be neces-
sary to prevent bystander B cells, that is those with no or
negligible afﬁnity for the immunising antigen, from persisting or
expanding in the GC. Moreover, we observed a transient pro-
duction of autoantibodies following exogenous antigenic chal-
lenge in our FcγRIIbwild/H1 KI mice, demonstrating that tight
regulation of FcγRIIb expression is necessary to maintain B-cell
tolerance44.
Here, we use an experimental system enabling us to monitor
the frequency of autoreactive (or potentially autoreactive) B cells
throughout B-cell differentiation and activation, in the context of
different levels of FcγRIIb expression and autoantigen exposure.
Our results show that a single inhibitory receptor can have
contrasting effects on different tolerance checkpoints, limiting
pre-immune while promoting post-immune tolerance. Our
results suggest a novel mechanism of GC tolerance, in which
FcγRIIb prevents the emergence of bystander autoreactive B cells.
Moreover, they also suggest that, in this context, GC tolerance is
dominant over pre-immune checkpoints for controlling the
development of autoimmunity.
Results
Reduced FcγRIIb expression increases central tolerance.
Absence or reduced expression of FcγRIIb on B cells has been
shown to drive autoimmunity. We thus set out to determine its
impact upon the different checkpoints of B-cell tolerance. We
used mouse strains expressing reduced, normal or increased levels
of FcγRIIb (FcγRIIb-deﬁcient mice (KO), FcγRIIb WT mice
(WT) and FcγRIIb-BFcR transgenic mice (BTG) that overexpress
FcγRIIb on B cells only40), crossed to the SWHEL mouse strain. In
SWHEL mice, a transgene encoding an Ig heavy chain speciﬁc for
the protein Hen Egg Lysozyme (HEL) has been knocked-in to the
endogenous heavy chain locus, allowing class-switching and
somatic hypermutation. These features, together with the fact that
SWHEL mice can generate a polyclonal immune response against
other antigens as only 10–30% of their B cells are speciﬁc for
HEL, enables the physiological tracking of a GC B-cell response
following immunisation45.
We ﬁrst evaluated the role of FcγRIIb in central tolerance
against a membrane-bound autoantigen using the membrane-
HEL (mHEL) mouse strain5. Lethally irradiated wild-type or
mHEL mice were reconstituted with bone marrow from SWHEL-
FcγRIIb KO, SWHEL-FcγRIIb WT or SWHEL-FcγRIIb BTG donor
mice (Fig. 1a). As previously described45, the frequency and
absolute number of HEL-speciﬁc BM immature B cells was
signiﬁcantly reduced in mHEL compared with wild-type
recipients irrespective of the donor used, consistent with clonal
deletion (Fig. 1b and Supplementary Fig. 1a). Interestingly,
deletion was enhanced in mHEL mice reconstituted with SWHEL-
FcγRIIb KO BM cells and reduced in mHEL mice reconstituted
with SWHEL-FcγRIIb BTG BM cells compared to WT controls
(Fig. 1c). Thus, reduced FcγRIIb expression increases the deletion
of autoreactive clones at the central tolerance checkpoint.
Reduced FcγRIIb expression enhances peripheral tolerance.
After leaving the BM, immature B cells experience another round
of selection at the transitional B-cell stage6. We thus determined
whether FcγRIIb expression had an effect on the frequency and
number of splenic HEL-speciﬁc immature and mature B cells
(Fig. 2a and Supplementary Fig. 1b, c). Absence of FcγRIIb
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expression was associated with more stringent counter-selection
of HEL-speciﬁc B cells at all stages from transitional T1 to mature
follicular and MZ B cells when compared with WT controls
(Fig. 2b–g). Supporting this observation, B cell-speciﬁc over-
expression of FcγRIIb was associated with increased frequency of
HEL-speciﬁc B cells in mHEL mice reconstituted with SWHEL-
FcγRIIb BTG BM cells compared with KO, and in some popu-
lations WT, groups, consistent with reduced tolerance at the
transitional T2/T3 (Fig. 2d) and mature follicular (Fig. 2e, f) B-
cell stages. Low but detectable levels of anti-HEL IgG1 were seen
in sera of unimmunised mHEL mice reconstituted with BM from
all SWHEL mice (Supplementary Fig. 1d). This observation makes
it possible that the effect of FcγRIIb on selection at this stage
might be driven by co-cross-linking of the BCR and FcγRIIb with
cognate antibody, although we cannot exclude an effect of
FcγRIIb on tonic BCR signalling independently of antigen
recognition and of FcγRIIb co-crosslinking46,47.
To conﬁrm the role of FcγRIIb in clonal deletion at these
central and peripheral tolerance checkpoints, we crossed the
SWHEL-FcγRIIb KO-CD45.2 and the SWHEL-FcγRIIb BTG-
CD45.1 mouse strains with mHEL mice (Supplementary Fig. 2).
In this experimental model, in contrast to BM chimeras where
HEL is only expressed by radiation-resistant recipient cells, all
cells including hematopoietic cells express the membrane-bound
HEL autoantigen. We observed a reduced frequency of HEL-
speciﬁc B cells in SWHEL-FcγRIIb-KO ×mHEL compared with
SWHEL-FcγRIIb-BTG ×mHEL mice (Supplementary Fig. 2b–e,
right panels), suggesting that reduced expression of FcγRIIb leads
to more potent clonal deletion regardless of which cells express
the autoantigen. Taken together, these results show that absence
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Fig. 1 Reduced FcγRIIb expression increases central tolerance. a Experimental procedure: wild-type and mHEL recipients (both CD45.2) were lethally
irradiated and reconstituted with bone marrow from SWHEL-FcγRIIb KO-CD45.2, SWHEL-FcγRIIb WT-CD45.1 or SWHEL-FcγRIIb BTG-CD45.1 donor mice.
b Representative ﬂow plots of immature B cells in the bone marrow (B220+IgM+, left top panel). B cells originating from the donor bone marrow were
identiﬁed based on FcγRIIb expression (detected with an anti-CD16/32 Ab) and expression of the congenic marker CD45.1 (right top panels). The
frequency of HEL-speciﬁc cells for each condition is showed using the smoothing function to help the visualisation of rare events (bottom panels).
c Quantiﬁcation of the frequency of HEL-speciﬁc immature B cells in WT (left panel) and mHEL (right panel) recipient mice. mHEL recipients: n= 12–19
mice per group; wt recipients: n= 8–11 mice per group. The mean is represented and each dot corresponds to an individual mouse. Four pooled
experiments are shown. The p-values were determined with the Kruskal–Wallis (KW) non-parametric test when comparing the three groups (KW: the p-
value is indicated in purple for the mHEL recipient. All KW tests were not signiﬁcant for WT recipients) and with the Mann–Whitney non-parametric test
when two conditions were compared (indicated by black stars). *p < 0.05; **p < 0.01; ***p < 0.001. Comparisons generating non-signiﬁcant p-values are
indicated with “ns”. Source data are provided as a Source Data ﬁle
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of or reduced FcγRIIb expression enhances clonal deletion at the
central and transitional B-cell peripheral tolerance checkpoints,
raising the question of how FcγRIIb deﬁciency leads to
autoimmunity.
FcγRIIb limits autoreactive B-cell anergy. We therefore tested
whether FcγRIIb expression controls B-cell anergy10,13,45 in
addition to clonal deletion. We measured anergy by ex vivo cross-
linking of the BCR and analysis of the phosphorylation of
a downstream kinase, normally reduced in anergic B cells. The
intensity of the phospho-Syk staining was equivalent between
HEL-speciﬁc (HEL+) and non-HEL-speciﬁc B cells (HEL−) in
WT recipients independent of FcγRIIb expression, that is, the
ratio of the geometric mean expression of phospho-Syk in HEL+
to HEL− B cells was 1 (Fig. 3a, b). This ratio was less than 1 in
KO WT BTG 
0
15
20
25
10
5
40
10
20
30
0
KO WT BTG
50
0
2
4
6
8
10
SWHEL
FcγRIIb: 
SWHEL
FcγRIIb: 
SWHEL
FcγRIIb: 
SWHEL
FcγRIIb: 
SWHEL
FcγRIIb: 
SWHEL
FcγRIIb: 
%
 H
E
L+
%
 H
E
L+
%
 H
E
L+
%
 H
E
L+
%
 H
E
L+
%
 H
E
L+
WT recipients mHEL recipients WT recipients mHEL recipients
Immature B cells (B220+CD93+) Mature B cells (B220+CD93–)
T1 B cells (B220+CD93+/CD23loIgDlo)
T2/T3 B cells (B220+CD93+/CD23hiIgDhi)
Follicular (B220+CD93–/CD21+CD23+)
KO WT BTG
0
2
4
6
Marginal zone (B220+CD93–/CD21hiCD23lo) 
a
b
c
d
e
f
g
C
D
93
 
B220 
Ig
D
CD23 
C
D
21
 
CD23 
B220+CD93+ B220+CD93–
B220
H
E
L
WT recipients mHEL recipients
SWHEL KO SWHEL WT SWHEL BTG SWHEL KO SWHEL WT SWHEL BTG 
B220+CD93– 
29.6 34.5 36.5 0.22 1.68 3.81 
CD45.1 
SWHEL KO SWHEL WT SWHEL BTG 
B220+CD93– 
87.6 89.7 82.1 
C
D
16
/3
2 
KW ***
p = 0.0008
KW ***
p = 0.0002
KW ****
p =<0.0001
KW ****
p =< 0.0001
KW **
p = 0.003
KW **
p = 0.0017
KO WT BTG
**** 
**** 
* 
*** 
* 
ns 
20
60
80
0
KO WT BTG
40
** 
** 
ns 
80
20
40
60
0
KO WT BTG 
ns ns 
ns 
100
20
40
0
KO WT BTG 
60
80
ns ns 
ns 
20
40
60
0
KO WT BTG
ns ns 
ns 
ns ns 
ns 
ns ns 
ns 
KO WT BTG 
20
0
10
40
*** 
** 
ns 
30
KO WT BTG 
20
60
100
0
ns ns 
ns 
80
40
KO WT BTG 
25
0
10
5
15
**** 
**** ns 
20
**** 
**
*** 
KO WT BTG 
0
10
6
8
4
2
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09434-0
4 NATURE COMMUNICATIONS |         (2019) 10:1970 | https://doi.org/10.1038/s41467-019-09434-0 | www.nature.com/naturecommunications
mHEL mice reconstituted with SWHEL-FcγRIIb-WT BM, con-
sistent with increased anergy among the remaining HEL+ B cells
that have avoided deletion (Fig. 3a, b). This ratio was further
reduced to 0.5 for mice reconstituted with SWHEL-FcγRIIb-KO
BM, demonstrating reduced phosphorylation of Syk upon BCR
engagement on HEL-autoreactive B cells in absence of FcγRIIb,
and conversely was around 1.5 for mHEL mice reconstituted with
SWHEL- FcγRIIb-BTG BM (Fig. 3a, b). Moreover, autoreactive
HEL+ B cells proliferated less than HEL− B cells in response to
LPS as shown by reduced CFSE dilution (Fig. 3c, d), and this
reduced proliferation was more marked in the absence of
FcγRIIb, suggesting that, indeed, FcγRIIb expression controls
autoreactive B-cell anergy (Fig. 3c, d). Consistent with this, the
frequency of HEL+ plasmablasts (CD138+B220lo) was higher in
mHEL recipients reconstituted with SWHEL-FcγRIIb-BTG and
SWHEL-FcγRIIb-WT than with SWHEL-FcγRIIb-KO BM (Fig. 3e,
f). Hence, our results show that absence of FcγRIIb expression
promotes increased anergy, with reduced signalling, proliferation
and differentiation of HEL-speciﬁc autoreactive B cells.
FcγRIIb limits autoreactive GC response against mHEL. Thus
FcγRIIb expression regulates pre-immune tolerance, with
FcγRIIb-deﬁcient mice showing enhanced deletion and anergy
compared with their control counterparts. This is at odds with the
observation that FcγRIIB defects are associated with auto-
immunity in both mice and humans, raising the question of
which tolerance checkpoint is defective in absence of FcγRIIB.
We therefore assessed GC tolerance, generating chimeras as
above and inducing GCs by immunising with HEL conjugated to
sheep red blood cells (SRBC-HEL) (Fig. 4a). Following SRBC-
HEL immunisation of mHEL recipients reconstituted with
SWHEL-FcγRIIb-KO BM cells, the frequency and number of
HEL-speciﬁc follicular B cells were reduced (Fig. 2, Supplemen-
tary Figs. 1 and 3, as expected, due to enhanced pre-immune
tolerance) but despite this, HEL-speciﬁc GC B-cell number was
increased compared with SWHEL-FcγRIIb-WT and SWHEL-
FcγRIIb-BTG controls (Fig. 4b–d). The ratio of the frequencies
of GC versus follicular HEL+ B cells was signiﬁcantly increased
in mHEL mice reconstituted with SWHEL-FcγRIIb-KO BM cells
compared with the two other experimental groups, emphasising
the large expansion of HEL-autoreactive GC B cells in the absence
of FcγRIIb (Fig. 4e). Despite this, the frequency and number of
TFH and TFR cells were not signiﬁcantly different (Supplementary
Fig. 4). To determine if this increase in HEL-speciﬁc autoreactive
GC B cells led to the development of HEL-speciﬁc plasma cells,
we performed ELIspot, and observed more HEL-speciﬁc anti-
body-forming cells (AFCs) in the spleen of mHEL recipients
reconstituted with SWHEL-FcγRIIb-KO BM compared with the
the SWHEL-FcγRIIb-WT and -BTG groups (Fig. 4f). The size and
intensity of the spots were similar between the different
experimental conditions (Supplementary Fig. 5), consistent with
equivalent antibody output and in vitro survival. Thus, despite a
mature B-cell repertoire shaped by enhanced clonal deletion and
anergy at pre-immune tolerance checkpoints, mice deﬁcient in
FcγRIIb have a marked defect in the negative-selection of
autoreactive GC B cells.
FcγRIIb limits autoreactive GC response against sHEL. To
assess if the inﬂuence of FcγRIIb on B-cell tolerance was
dependent on the strength of BCR signalling, we next used mL5
transgenic mice that express soluble HEL, which binds the BCR
with less avidity than mHEL2, as an autoantigen (Fig. 5a). As
expected from the previous studies2, the deletion of HEL-speciﬁc
B cells was less pronounced in mL5 recipients compared with
mHEL recipients (Figs. 1, 2 and 5). Nevertheless, deﬁcient
FcγRIIb expression still reduced the frequency of HEL-speciﬁc
BM immature B cells in mice reconstituted with SWHEL-FcγRIIb-
KO compared with SWHEL-FcγRIIb-WT or SWHEL-FcγRIIb-BTG
BM (Fig. 5b). The frequency and number of HEL-speciﬁc auto-
reactive B cells in the marginal zone were also decreased in
absence of FcγRIIb (Fig. 5d) compared with SWHEL-FcγRIIb-
BTG BM, whereas the frequency and number of autoreactive
non-GC follicular B cells was not signiﬁcantly affected by FcγRIIb
expression (Fig. 5c).
Following immunisation, we observed an increase in the
number of HEL-speciﬁc GC B cells (Fig. 5e) and in the ratio of
HEL-speciﬁc GC to follicular B cells (Fig. 5f) in sHEL recipient
mice reconstituted with SWHEL-FcγRIIb-KO BM compared with
mice reconstituted with SWHEL-FcγRIIb-BTG BM. Finally, sHEL
recipients reconstituted with SWHEL-FcγRIIb-KO BM had an
increased number of HEL-speciﬁc AFCs compared with the two
other groups (Fig. 5g). Thus, whether autoantigen is soluble or
membrane-bound, FcγRIIb deﬁciency enhances pre-immune and
reduces GC tolerance.
FcγRIIb controls bystander autoreactive GC B cells. We pre-
viously generated a knock-in mouse model bearing naturally
occurring polymorphisms of the Fcgr2b promoter common in
wild mice and associated with spontaneous autoimmunity in
inbred strains. These FcγRIIbwild/H1 KI mice have defective
upregulation of FcγRIIb upon activation, leading to an increase in
total GC B cell number, but no change in the number of antigen-
speciﬁc GC B cells after a T-dependent immunisation44. This
suggested that FcγRIIb expression might regulate the number of
bystander GC B cells, that is, those displaying no or very low
afﬁnity for the immunising antigen. Moreover, the FcγRIIbwild/H1
KI mice also produced anti-dsDNA and anti-chromatin auto-
antibodies transiently following exogenous antigenic challenge44.
Consistent with this, SRBC immunised FcγRIIb-deﬁcient mice
produced signiﬁcantly more anti-dsDNA autoantibodies than
BTG mice (Fig. 6a). These ﬁndings raised the possibility that
FcγRIIb might contribute to GC tolerance by restricting the
Fig. 2 Reduced FcγRIIb expression increases peripheral tolerance at the transitional B-cell stage. a Representative ﬂow plots of immature and mature B cells
in the spleen: immature and mature B cells were identiﬁed as B220+CD93+ and B220+CD93−, respectively. Amongst the immature B cells, transitional T1
and T2/T3 were identiﬁed based on the expression of IgD and CD23 (T1= IgDloCD23lo; T2/T3: IgDhiCD23hi). Mature B cells were separated as follicular
(CD23+CD21+) and marginal zone (CD23loCD21hi) (left top three panels). On each subset, B cells originating from the donor bone marrow were identiﬁed
based on the expression of FcγRIIb (CD16/32) and of the congenic marker CD45.1 (right top three panels). The frequency of HEL-speciﬁc cells was
determined (bottom panels). b–g Quantiﬁcation of the frequency of HEL-speciﬁc B cells in WT (left panel) and mHEL (right panel) recipient mice: total
immature B cells (b), T1 transitional B cells (c), T2/T3 transitional B cells (d), total mature B cells (e), follicular B cells (f) and marginal zone B cells
(g). mHEL recipients: n= 14–20 mice per group; wt recipients: n= 7–8 mice per group. The mean is represented and each dot corresponds to an individual
mouse. Four pooled experiments are shown. The p-values were determined with the Kruskal–Wallis (KW) non-parametric test when comparing the three
groups (KW: the p-value is indicated in purple for the mHEL recipient. All KW tests were not signiﬁcant for the WT recipients) and with the Mann–Whitney
non-parametric test when two conditions were compared (indicated by black stars). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Comparisons
generating non-signiﬁcant p-values were indicated with “ns”. Source data are provided as a Source Data ﬁle
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generation of autoreactive cells arising as bystanders in a GC
reaction to non-self antigens.
We then asked whether, in the absence of FcγRIIb expression,
autoreactive bystander B cells could expand in the GC in response
to exogenous antigen and generate autoantibodies. We crossed the
mHEL strain to the Rag2−/− background (ensuring all B cells were
of BM donor origin, allowing precise quantiﬁcation of rare HEL-
speciﬁc GC B cells and serum HEL-speciﬁc antibodies), irradiated
both Rag2−/− and Rag2−/− mHEL mice sub-lethally, and
reconstituted them with SWHEL-FcγRIIb-KO, -WT or -BTG BM
cells (Fig. 6b). As expected, enhanced pre-immune tolerance
resulted in fewer HEL-speciﬁc B cells in mHEL recipient mice
reconstituted with SWHEL-FcγRIIb-KO compared with SWHEL-
FcγRIIb-WT and SWHEL-FcγRIIb-BTG BM cells (Fig. 6c). How-
ever, SRBC immunisation drove an increase in HEL-speciﬁc GC B
cells (Fig. 6d) and in serum HEL-speciﬁc IgG1 (Fig. 6e) in Rag2−/−
mHEL mice reconstituted with SWHEL-FcγRIIb-KO BM compared
with SWHEL-FcγRIIb-WT and -BTG BM cells.
We next wondered if this bystander autoimmunity could be
observed in a more physiological context, and thus performed
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Fig. 3 Absence of FcγRIIb expression enhances autoreactive B-cell anergy. a Representative histograms of phospho-Syk on HEL-speciﬁc (HEL+, red
histograms) and HEL-non speciﬁc (HEL−, blue histograms) splenic B cells from WT and mHEL recipient chimeras reconstituted with SWHEL-FcγRIIb KO,
SWHEL-FcγRIIb WT and SWHEL-FcγRIIb BTG BM and measured by ﬂow cytometry after BCR cross-linking. A dashed line indicates the staining without
stimulation. b Quantiﬁcation of phospho-Syk after cross-linking of the BCR. For each sample, the geometric mean of the phospho-Syk staining without
stimulation was subtracted from the one after stimulation. We used this corrected mean to calculate for each mouse the ratio of phospho-Syk staining in
HEL+ by HEL− B cells (Δmean phospho-Syk). c Representative histograms of CFSE dilution on HEL-speciﬁc (HEL+, red) and HEL-non speciﬁc (HEL−,
blue) splenic B cells from WT and mHEL recipient chimeras reconstituted with SWHEL-FcγRIIb KO, SWHEL-FcγRIIb WT and SWHEL-FcγRIIb BTG BM 4 days
after LPS stimulation. d CFSE dilution was quantiﬁed by ﬂow cytometry on HEL+ and HEL− B cells. For each mouse, we calculated the ratio of the
geometric mean of the CFSE staining on HEL+ by HEL− B cells (Δmean CFSE). e Representative gating of plasmablasts (left panel) and HEL+ plasmablasts
(right panels) from mHEL recipient chimeras reconstituted with SWHEL-FcγRIIb KO, SWHEL-FcγRIIb WT and SWHEL-FcγRIIb BTG BM 4 days after LPS
stimulation. f B-cell differentiation after LPS stimulation was measured by quantifying the frequency of HEL+ plasmablasts. For a, b, three experiments
were pooled. Wild-type recipients: n= 7–8 mice/group; mHEL recipients: n= 11–12 mice/group. For c–e, two experiments were pooled. Wild-type
recipients: n= 2 mouse/group; mHEL recipients: n= 6 mice/group. The mean is represented and each dot corresponds to an individual mouse. The p-
values were determined with the Kruskal–Wallis (KW) non-parametric test when comparing the three groups (KW: the p-value is indicated in purple for
the mHEL recipient. All KW tests were not signiﬁcant for WT recipients) and with the Mann–Whitney non-parametric test when two conditions were
compared (indicated by black stars). *p < 0.05; **p < 0.01; ***p < 0.001. Comparisons generating non-signiﬁcant p-values were indicated with “ns”. Source
data are provided as a Source Data ﬁle
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similar experiments with the SWHEL-FcγRIIbwild/H1 KI mice
containing naturally occurring promoter Fcgr2b variations
(Supplementary Fig. 6a). We had shown previously that these
mice displayed subtly reduced FcγRIIb expression on pre-B,
immature and GC B cells, suggesting these natural Fcgr2b
polymorphisms may impact upon both pre-immune and GC
tolerance44. The results followed the same trend as those
generated using SWHEL-FcγRIIb KO chimeras. There was
enhanced tolerance at the pre-immune checkpoints (reduced
frequency of HEL-speciﬁc autoreactive B cells in the BM and
spleen of SWHEL-FcγRIIbwild/H1 KI/mHEL mice compared with
control (Supplementary Fig. 6b, c). Despite this, in the SWHEL-
FcγRIIbwild/H1 KI chimeric mice immunised with SRBC, the total
number of HEL-speciﬁc GC B cells as well as the ratio of HEL-
donor bone marrow 
WT (CD45.2)
or mHEL (CD45.2)
recipients 
Immunisation with SRBC-HEL i.p. and analysis at day 8
a SWHEL–FcγRIIb KO-CD45.2
or SWHEL–FcγRIIb BTG-CD45.1
or SWHEL–FcγRIIb WT-CD45.2 
b
B220
H
EL
WT recipients mHEL recipients
16.5 11.8 13.1 4.92 2.74 2.48 
CD19+
FA
S
GL7 CD45.1
CD
16
/3
2 
CD19+/FAShiGL7hi
CD19+/FAShiGL7hi
83.8 
89.7 
0.77 0.5 84.5 
0.015 
17.6 13.6 12.1 
SWHEL KO SWHEL WT SWHEL BTG
SWHEL KO SWHEL WT SWHEL BTGSWHEL KO SWHEL WT SWHEL BTG
SWHEL KO SWHEL WT SWHEL BTG
c mHEL recipients
GC B cells (B220+/GL7hiFAShi)
KW  
p = 0.63 
0
2
4
6 ns ns 
ns 
KO WT BTG
WT recipients
%
 H
EL
+
0
10
20
30 ns ns 
ns 
KO WT BTG
SWHEL
FcγRIIb:
d WT recipients mHEL recipients
GC B cells (B220+/GL7hiFAShi)
0
15
10
5
KO WT BTG
*
ns 
*
KW * 
p = 0.05 
0
20
10
30
KO WT BTG
H
EL
+
 
ce
lls
(nu
mb
er 
×1
04
)
*
ns 
ns 
KW ** p = 0.0043
40
50
SWHEL
FcγRIIb:
e 
%
 H
EL
+
0
1.5
1.0
KW **  
p = 0.0016 
*** 
* 
* 
0.5
2.0
0
20
10
30
40
ns ns 
ns 
50
KO WT BTGKO WT BTG
FO B cells (B220+/CD21+CD23+)
SWHEL
FcγRIIb:
KO WT BTG
0
40
20
60
80
* 
ns 
* 
KW * 
p = 0.029 
g
H
EL
+
 
AF
Cs
/
5×
10
6  
ce
lls
ELISpot
KO WT BTG
0
30
20
10
ns ns 
ns 
SWHEL
FcγRIIb:
f
KO WT BTG
KW *** 
p = 0.0004
Ratio GC/Follicular B cells 
0 
10 
15 
*** 
** 
* 
5 
KO WT BTG
0
0.5
1.0
1.5
%
 H
EL
+
(R
ati
o G
C/
FO
) ns ns 
ns 
2.0
SWHEL
FcγRIIb:
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09434-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1970 | https://doi.org/10.1038/s41467-019-09434-0 | www.nature.com/naturecommunications 7
speciﬁc GC B cells to total splenic B cells were increased
(Supplementary Fig. 6d, e). A non-signiﬁcant trend towards
increased serum HEL-speciﬁc autoantibodies in mice reconsti-
tuted with SWHEL-FcγRIIbwild/H1 KI BM was also observed
(Supplementary Fig. 6f). In summary, a naturally occurring
genetic variant reducing the FcγRIIb increase that follows B-cell
activation can drive the expansion of autoreactive B cells in the
GC, despite enhanced pre-immune tolerance and even in
response to an irrelevant exogenous antigen.
FcγRIIB limits VH4-34 gene usage in humans. We then asked
whether FcγRIIB had a similar impact on tolerance checkpoints
in humans. We used the National Institute of Health Research
(NIHR) Cambridge BioResource to recruit 29 healthy volunteers:
19 volunteers homozygous for isoleucine at position 232 in
FCGR2B (hereafter referred to as I232 individuals), the common
variant associated with normal FcγRIIB function, and 10 volun-
teers homozygous for the SLE-associated single-nucleotide poly-
morphism in FCGR2B (hereafter referred to T232 individuals)
encoding a receptor that has markedly reduced inhibitory
function21,22. We ﬂow-sorted peripheral blood CD19+IgD+
CD27− naive/transitional B cells; CD19+IgD−CD27−CD38mid/hi
activated B cells; CD19+IgD+CD27+ B cells that include mar-
ginal zone B cells, and perhaps B1-like and unswitched memory
cells48–51; CD19+IgD−CD27+CD38low/mid memory B cells; and
CD19+IgD−CD27+CD38hi plasmablasts (Supplementary Fig. 7).
The BCR repertoire for each of these subsets was analysed by
high-throughput sequencing using a method that can distinguish
between isotype classes (Supplementary Fig. 8 and 52), generating
an average of 20,573 BCR sequences per B-cell subset (Supple-
mentary Table 1).
No signiﬁcant differences in the proportion of B cells within
each B-cell subset, nor of isotype usage, was seen between
genotypes (Supplementary Figs. 9 and 10). The effect of FcγRIIB
on tolerance was evaluated by examining the frequency of cells
expressing the IgHV4-34 gene. This speciﬁc heavy chain has been
shown to bind red blood cell antigens53,54 as well as commensal
bacteria55, and was signiﬁcantly enriched in SLE patients (Fig. 7a)
in agreement with previous studies56,57. Moreover, IgHV4-34 was
enriched among BCRs without sequence evidence of switching or
SHM (comprising predominantly naive B cells), as well as
antigen-experienced BCRs as evidenced by isotype switching or
SHM, suggesting a defect in both pre- and post-immune
tolerance (Fig. 7a).
In I232 healthy volunteers, the frequency of IGHV4-34 gene
usage was higher in CD19+IgD+CD27− than in CD19+
IgD−CD27−CD38mid/hi and CD19+CD27+IgD− populations
(Fig. 7b), consistent with the impact of peripheral tolerance on
this autoreactive population. Healthy T232 and I232 individuals
had similar IGHV4-34 proportions in CD19+IgD+CD27− cells,
suggesting the enhanced central tolerance seen in FcγRIIB-deﬁcient
mice may not occur in humans. IGHV4-34 was, however, enriched
in CD19+CD27+IgD+ and CD19+IgD−CD27−CD38mid/hi popu-
lations to a level similar to that seen in SLE patients (Fig. 7b), and
consistent with impaired post-immune tolerance associated with
FcγRIIB dysfunction, though this difference was not seen in the
CD19+IgD−CD27+CD38low/mid population. These human data
suggest that, even in a healthy heterogeneous population, reduced
FcγRIIB function impacts upon post-immune, rather than central/
pre-immune tolerance, consistent with the differential impact of
FcγRIIB on pre- and post-immune tolerance seen in the mouse, but
with notable species-speciﬁc differences.
Discussion
Immune tolerance in B cells is governed by a number of check-
points that share the common goal of preventing the emergence
of autoreactive lymphocytes. Given this shared goal, it might
seem likely that molecules that regulate tolerance would
impact upon different tolerance checkpoints in a similar direc-
tion. One such molecule is FcγRIIb, an inhibitory receptor
that antagonises BCR signalling. Its reduced expression or func-
tion enhances BCR signalling and also predisposes to auto-
immunity in mouse and human. To investigate the role of
FcγRIIb in the development of autoimmunity, we used mice
either under- or overexpressing FcγRIIb on their B cells, crossed
to the SWHEL mouse model to allow interrogation of speciﬁc
tolerance checkpoints.
Three distinct mouse models were used in this study, as each
alone had inherent limitations. The FcγRIIb-deﬁcient mouse has
a profound defect affecting not only B cells, but also other cells
implicated in the immune response35,37. We therefore also used
two additional models. In one FcγRIIb was over-expressed on all
B cells by between two- and tenfold (but was expressed at normal
levels on other cell types40). The other is a more physiological
model of FcγRIIb under-expression, in which a knock-in of a
naturally occurring promoter variant results in a failure of
activation-induced upregulation of FcγRIIb speciﬁcally on B
cells44. This genetic model would be expected to give a less
extreme phenotype than the deﬁcient mice, as its defect is subtle,
but would conﬁrm the B-cell speciﬁcity of any effect. Taken
together comparisons between these three models increase con-
ﬁdence in our ﬁndings, as they provide conﬁrmation in two
under-expression models—one an extreme knockout, and one a
subtle B-cell speciﬁc physiological genetically modiﬁed mouse—
and a cell-speciﬁc overexpression model.
Fig. 4 FcγRIIb limits autoreactive GC response despite more stringent pre-immune tolerance. a Wild-type and mHEL recipients (both CD45.2) were
irradiated and reconstituted with the bone marrow from SWHEL-FcγRIIb KO-CD45.2, SWHEL-FcγRIIb WT-CD45.1 or SWHEL-FcγRIIb BTG-CD45.1 donor
mice. Post reconstitution, chimeras were immunised with SRBC-HEL intraperitoneally and analysed 8 days later. b Representative ﬂow plots of GC B cells
(top panels) in the spleen of immunised chimeric mice. GC B cells were gated as CD19+/FAShiGL7hi. B cells originating from the donor bone marrow were
detected by the level of FcγRIIb expression (CD16/32) and by the congenic marker CD45.1 (top right three panels) and the frequency of HEL-speciﬁc cells
was measured (bottom panels). c, d Quantiﬁcation of the frequency and number of HEL-speciﬁc GC B cells in WT (left panels) and mHEL (right panels)
recipient mice. e Quantiﬁcation of the frequency of HEL-speciﬁc follicular B cells in WT (left panels) and mHEL (right panels) recipient mice. f Ratio of the
frequency of HEL-speciﬁc GC B cells and total follicular B cells in WT (left panel) and mHEL recipient mice (right panel). g Quantiﬁcation by ELISpot of
HEL-speciﬁc antibody-forming cell (AFC) numbers in the spleen of immunised WT (left panels) and mHEL (right panels) recipient mice. For all panels two
experiments were pooled. For panels (c–f), wild-type recipients: n= 5–6 mice per group; mHEL recipients: n= 8–11 mice per group. For panel (g), wild-type
recipients: n= 5 mice per group; mHEL recipients: n= 6–9 mice per group. The mean is represented and each dot corresponds to an individual mouse. In
panel b, the FlowJo smoothing option was used to improve visibility due to low event rates. The p-values were determined with the Kruskal–Wallis (KW)
non-parametric test when comparing the three groups (KW: the p-value is indicated in purple for the mHEL recipient. All KW tests were not signiﬁcant for
WT recipients with the exception of panel d, for which the KW p-value is indicated for the WT group as well) and with the Mann–Whitney non-parametric
test when two conditions were compared (indicated by black stars). *p < 0.05; **p < 0.01; ***p < 0.001. Comparisons generating non-signiﬁcant p-values
were indicated with “ns”. Source data are provided as a Source Data ﬁle
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In both major pre-immune tolerance checkpoints, at the BM
immature B-cell stage and at the transitional B-cell stage in the
spleen, no or low-FcγRIIb expression was associated with more
stringent tolerance, with increased deletion and anergy of HEL-
speciﬁc autoreactive B cells. In contrast, such reduced FcγRIIb
expression was associated with the increased production of
autoreactive B cells in the GC, and in serum autoantibody, con-
sistent with a failure of tolerance at the GC checkpoint.
FcγRIIB is expressed not only on B cells, but on other hemato-
poietic cells, such as macrophages and dendritic cells. Chimeras
reconstituted with FcγRIIb KO BM will therefore contain non-B
cells that are FcγRIIb deﬁcient. The impact of FcγRIIb on tolerance,
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Fig. 5 The impact of FcγRIIb on GC tolerance is also observed with a soluble autoantigen. a Wild type and sHEL recipients (both CD45.2) were irradiated
and reconstituted with bone marrow from SWHEL-FcγRIIb KO-CD45.2, SWHEL-FcγRIIb WT-CD45.1 or SWHEL-FcγRIIb BTG-CD45.1 donor mice. Post
reconstitution, chimera were immunised with SRBC-HEL intraperitoneally and analysed 8 days later. All populations were gated as in Figs. 1, 2 and 4. b–e
Quantiﬁcation of the frequency of HEL-speciﬁc B cells in WT (left panels) and sHEL (right panels) recipient mice: BM immature B cells (b), splenic mature
MZ B cells (c), splenic follicular B cells (d) and splenic GC B cells (e). f Ratio of HEL-speciﬁc GC B cells and total follicular B cells in WT (left panel) and
sHEL recipient mice (right panel). g Quantiﬁcation by ELISpot of HEL-speciﬁc antibody-forming cells (AFCs) in the spleen of immunised WT (left panels)
and sHEL (right panels) recipient mice. sHEL recipients: n= 4–6 mice per group; wt recipients: n= 2–3 mice per group. One experiment representative of at
least two is shown. The mean is represented and each dot corresponds to an individual mouse. The p-values were determined with the Kruskal–Wallis
(KW) non-parametric test when comparing the three groups (KW: the p-value is indicated in purple for the mHEL recipient. All KW tests were not
signiﬁcant for WT recipients with the exception of panel e (absolute number) for which KW p-value is indicated for the WT group as well) and with the
Mann–Whitney non-parametric test when two conditions were compared (indicated by black stars). *p < 0.05; **p < 0.01. Comparisons generating non-
signiﬁcant p-values were indicated with “ns”. Source data are provided as a Source Data ﬁle
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Fig. 6 FcγRIIb expression controls bystander autoreactive GC B-cell expansion. a Serum dsDNA-speciﬁc IgG1 titer in KO-CD45.2, WT-CD45.2 or BTG-
CD45.1 mice immunised for 8 days with SRBC. (R.U. = relative units) b RAG2KO and RAG2KO-mHEL recipients (both CD45.2) were irradiated and
reconstituted with bone marrow from SWHEL-FcγRIIb KO-CD45.2, SWHEL-FcγRIIb WT-CD45.2 or SWHEL-FcγRIIb BTG-CD45.1 donor mice. Post
reconstitution, chimeras were immunised with SRBC intraperitoneally and analysed 8 days later. c Number of HEL-speciﬁc follicular B cells in RAG2KO (left
panel) and RAG2KO-mHEL (right panel) recipient mice. d Number of HEL-speciﬁc GC B cells in RAG2KO (left panel) and RAG2KO-mHEL (right panel)
recipient mice. e Serum HEL-speciﬁc IgG1 titer in RAG2KO (left panel) and RAG2KO-mHEL (right panel) recipient mice. Two pooled experiments are
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panel c for which KW p-value is indicated for the RAG2KO group as well) and with the Mann–Whitney non-parametric test when two conditions were
compared (indicated by black stars). *p < 0.05; **p < 0.01. Comparisons generating non-signiﬁcant p-values were indicated with “ns”. Source data are
provided as a Source Data ﬁle
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however, is likely to be B cell intrinsic for several reasons. The ﬁrst
is that we observed a similar effect on tolerance in chimeras
reconstituted with BM from SWHEL Fcgr2bwild/H1 KI mice, in
which FcγRIIB expression is reduced only on B cells44. The second
is that transgenic overexpression of FcγRIIb on B cells alone leads to
the opposite phenotype, with very strong tolerance at the immature
stage despite less stringent GC tolerance. Finally, we also performed
our BM reconstitution experiments in Rag2−/− recipient mice that
were non-lethally irradiated. In consequence, cells other than B and
T lymphocytes were mostly coming from the recipients that were
WT for FcγRIIb expression.
The two pre-immune checkpoints were similarly inﬂuenced by
FcγRIIb expression, suggesting a shared mechanism distinct from
that in the GC. Co-ligation of FcγRIIb to the BCR by cognate
antibody is known to inhibit BCR signalling. It is also clear,
however, that in immature B cells FcγRIIb can inhibit the BCR
independent of cross-linking by antibody46. As we observed
detectable levels of anti-HEL IgG1 in relevant mice, it is plausible
that they are involved in co-ligation of FcγRIIb to the HEL-
speciﬁc BCR. It is also possible that FcγRIIb may be having its
impact through tonic inhibitory signals. Whether or not the
impact of FcγRIIb on selection at the immature/transitional B-cell
stage is dependent upon antibody ligation of FcγRIIb, therefore
remains an open question.
Our results demonstrate that tolerance in the GC cannot be
mediated solely by a deletion of autoreactive clones driven by BCR
signal strength as occurs in the BM, as earlier studies might have
implied7,15–17, as the impact of reduced FcγRIIb on BCR signal-
ling should enhance such tolerance. By demonstrating FcγRIIb
deﬁciency increased HEL-speciﬁc GC B cells in response to SRBC
in mice that had never been exposed to HEL, we conﬁrmed our
earlier suspicion44 that FcγRIIb controlled the expansion of
bystander B cells in the GC. Such bystander cells, with no mea-
surable afﬁnity for the immunising antigen, have recently been
implicated in contributing to ongoing GCs58,59, supporting our
observation. It should be noted, however, that while low afﬁnity
cross-reactivity between the transgenic anti-HEL BCR and SRBC
antigens cannot be measured, and would seem unlikely, the pre-
sence in the bystander population of cells with very low afﬁnity for
a given antigen cannot be excluded, and could contribute to
subsequent measurable bystander responses. Nonetheless, no or
low expression of FcγRIIb led to the presence of autoreactive cells
into the GC that could differentiate into AFCs that produced
isotype-switched autoantibody detectable in the serum in response
to a distinct exogenous antigen. This could explain the appearance
of autoantibodies sometimes noted after infection or inﬂammation
in humans60,61, which is presumably impacted by genetic back-
ground. Most importantly, it points to a potential novel
mechanism-governing tolerance and the development of auto-
immunity in the GC—the control of bystander activation and
expansion of autoreactive B cells in the GC could be a central
mechanism for avoiding autoimmunity, and one in which inhi-
bitory receptors such as FcγRIIb play an important role. A recent
paper by Silver et al. has formally demonstrated, using a mouse
transgenic system, that non-cognate B cells can enter the GC and
diversify via somatic hypermutation even in a competitive setting,
and can then generate new antigenic speciﬁcities and ongoing
immune responses58. This mechanism was proposed to have
perhaps arisen to ﬁll holes in the B-cell repertoire, and thus
improve defence against infection. Our data suggest it could also
be responsible for generating autoreactive responses, and perhaps
also for the GC-driven autoantigen spreading recently described
by Carroll and colleagues59. Thus, the generation of autoimmunity
by bystander activation of B cells is consistent with previous
observations in the setting of both non-autoreactive and auto-
reactive immune responses. Further work will be required to
determine the precise molecular mechanisms at play.
The results presented here might make the concepts of pre-
immune and post-immune tolerance a more logical way of sub-
dividing tolerance than the more traditional central versus per-
ipheral tolerance nomenclature. This constitutes an example of a
regulatory receptor having opposing effects on pre- and post-
immune B-cell tolerance. It could be envisaged that other mole-
cules that regulate BCR signal strength may also have different
impacts upon tolerance checkpoints, as, for example, was repor-
ted for a Ptpn22 risk mutant that differentially regulates auto-
reactive follicular and marginal zone B cells62. The net outcome
of FcγRIIb deﬁciency in the B-cell compartment is autoimmunity,
demonstrating that in this particular context post-immune tol-
erance is dominant over pre-immune tolerance.
This seems also to be the case in humans, as complementary
ﬁndings were made in healthy volunteers bearing a loss-of-
0
5
10
15
20 ***
0
5
10
15
20 **
0
5
10
15
20 ***
a
%
 IG
H
V
4-
34
 V
H
s 
pe
r 
su
bs
et
 
From total PBMCs 
IgD or IgM
unmutated
IgD or IgM
mutated
Class-switched
(IgA/E/G)
H
ea
lth
y
S
LE
H
ea
lth
y
S
LE
H
ea
lth
y
S
LE
0
2
4
6
8
10
12
14
NS * * NS
***
NS
**
%
 IG
H
V
4-
34
 V
H
 p
er
 s
ub
se
t 
b
CD27–
IgD+ 
CD27– IgD–
CD38mid/hi
CD27+
IgD+ 
CD27+ IgD–
CD38low/mid 
FCGR2B-I232 
FCGR2B-T232
Fig. 7 Effect of FCGR2B genotype on the IGHV gene repertoire in humans. a Percentage of IGHV4-34 gene usage from IgH sequencing from total PBMCs
from healthy individual versus SLE patients during active disease, grouped according to IgH subtype: unmutated IgD or IgM IgH sequences, which are
largely derived from naive B cells; mutated IgD or IgM IgH sequences which are derived from B cells having undergone SHM, thus evidence of antigenic
stimulation; and class-switched IgH sequences, therefore derived from B cells post-antigenic stimulation. b Percentage of IGHV4-34 gene usage in cell-
sorted populations from FCGR2B genotyped healthy individuals per population. * denotes differences between genotypes or cell subsets with p-values <
0.05, ** denotes p-values < 0.005, *** denotes p-values < 0.0005 (by ANOVA with age as a covariate), NS: non-signiﬁcant p-values
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09434-0 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1970 | https://doi.org/10.1038/s41467-019-09434-0 | www.nature.com/naturecommunications 11
function variant in FCGR2B. The proportion of IGHV4-34 clones,
known to be autoreactive, was signiﬁcantly higher in the activated
CD19+IgD−CD27−CD38mid/hi and CD19+IgD+CD27+ B-cell
subsets in individuals homozygous for the FCGR2B T232 loss-of-
function SLE-associated polymorphism. This is consistent with a
relative impairment of post-immune tolerance in people with
reduced FcγRIIB function, as was seen in mice. Mouse and
human results were not fully concordant (there was, for example,
no evidence in humans of increased pre-immune tolerance
associated with reduced FcγRIIb function, at least as this is
reﬂected in IGHV4-34 clone frequency). Nonetheless, human
data support a predominant role for FcγRIIB in post-immune
tolerance, as was seen in the various mouse models.
This unexpected complexity of checkpoint control in B-cell tol-
erance points to a nuanced regulation of the balance between the
risk of autoreactivity and the maintenance of repertoire breadth to
optimise defence against infection. It may also have implications for
the increasingly sophisticated attempts to manipulate the B-cell
immune response following the success of B-cell depletion by
rituximab in autoimmune disease. The possibility that a given
inhibitory receptor may have opposing effects on the generation of
autoreactivity at different checkpoints in different contexts may
impact upon therapy targeted at inhibitory receptors, helping
explain the mechanism of new therapeutic agents (e.g. anti-CD22
therapy epratuzumab, which generated unexpected dose-related
complexity in clinical studies63), but perhaps also creating oppor-
tunities for synergistic therapies targeting individual checkpoints.
Methods
Mice. The SWHEL mice were a kind gift of Robert Brink. They were crossed with
the FcγRIIb-deﬁcient mouse strain35, the FcγRIIb-BTG strain (itself crossed to the
CD45.1 background)40 and the FcγRIIb wild/H1 KI mouse strain44. FcγRIIb KO
mice (C57BL/6 FcγRIIb−/−) were provided by J. Ravetch and S. Bolland. This
strain was originally generated on the 129/sv background and backcrossed for more
than 15 generations on the C57BL/6 background. Despite this extensive back-
crossing, we cannot exclude the persistence of 129/sv-derived polymorphisms in
the Fcgr2b genetic region. Nevertheless, as we also used the FcγRIIb-BTG and the
FcγRIIbwild/H1 KI strains that were both generated on pure C56BL/6 background,
we are conﬁdent that the results observed are indeed due to the level of expression
of FcγRIIb. Fcgr2b is on the same chromosome than the Ly5 locus, making it very
difﬁcult to obtain FcγRIIb KO mice bearing the congenic marker CD45.1. The
mHEL (membrane-bound HEL transgenic) and ML5 (soluble HEL transgenic)
mice have been described previously2,5. We crossed the mHEL strain with the
Rag2−/− (here called RAG2KO) strain to obtain the mHEL × RAG2KO strain,
expressing one allele of the mHEL transgene. For all experiments, the number of
animals included in each experiments was determined based on our previous
expertise using mouse models with different expression level of FcγRIIb and by
using the G*Power software for a priori power calculation.
To generate bone marrow chimeras, recipient mice were irradiated lethally
(1000 Gy for WT, mHEL and mL5 recipients) or sub-lethally (500 Gy for RAG2KO
and mHEL × RAG2KO recipients) and reconstituted by intravenous injection of
fresh bone marrow cells. Reconstitution was assessed 6 weeks later and mice that
were not reconstituted fully were excluded. Reconstituted mice were randomly
numbered independently of their genotype or BM used for their reconstitution and
analysed at least 8 weeks post irradiation. Mice were immunised with sheep red
blood cells (SRBC) conjugated with HEL or SRBC alone by intra-peritoneal
injection, as indicated64. All experiments were performed according to the
regulations of the UK Home Ofﬁce Scientiﬁc Procedures Act (1986) and
permission was given by the UK Home Ofﬁce to perform such procedures at our
local animal facility.
Flow cytometry. Single cell suspensions of the spleen and bone marrow were pre-
pared by mashing or ﬂushing the organs, respectively44. For phosphoﬂow staining,
splenocytes were stimulated at 37 °C for 5min with a F(ab’)2 goat anti-mouse IgG
(H+ L) antibody (from Jackson immunosearch, 10 μg/ml). Cells were then ﬁxed with
ice-cold methanol on ice for 30min before staining with the relevant antibodies. HEL-
speciﬁc B cells were detected by staining with either recombinant HEL (40 ng/ml,
Sigma-Aldrich) followed by a rabbit anti-HEL biotinylated (AbCam) and streptavidin
eFluor450 (eBioscience) or 1 μg/ml of biotinylated HEL (conjugation with the EZ-link
Sulfo-NHS-biotin kit from Pierce following the manufacturer’s instructions) and
streptavidin eFluor450 (eBioscience). For all experiments, the gating of HEL-binding
cells was set up based on control staining with a biotinylated rabbit anti-HEL and
streptavidin eFluor450, or streptavidin eFluor450 alone when biotinylated HEL was
used. For the analysis, the HEL+ gates were drawn on the condition minus HEL and
applied to all other samples.
FACS analysis was performed on a BD LSR Fortessa (BD biosciences) and data
were analysed with the Flowjo software (TreeStar, Ashland, OR). All antibodies
used are described in Supplementary Table 2.
ELISA and ELISPOT. Serum HEL-speciﬁc IgG1 were detected by ELISA using a
modiﬁed version of the protocol previously described44. Brieﬂy, plates were coated
with 5 μg/ml of HEL in PBS overnight at 4 °C. Sera were added to the saturated
plates and were incubated for 2 h at 37 °C. Pooled sera from hyperimmune mice
(immunised with SRBC-HEL twice) were used as a standard. Plates were developed
with the BD Opteia kit (BD Biosciences). Serum dsDNA-speciﬁc IgG1 was detected
by ELISA as previously described65.
For detection of HEL-speciﬁc antibody-forming cells (AFCs) ELISPOT plates
(Millipore) were coated with 5 μg/ml of HEL in PBS overnight at 4 °C. Single-cell
suspensions of the spleen were added to saturated ELISPOT plates in quadruplicate
and incubated overnight at 37 °C in 5% CO2 in a humidiﬁed incubator with culture
medium. AFCs were detected with goat anti-mouse IgG1 antibody conjugated to
horseradish peroxidase (Southern Biotech). Plates were developed using 3-amino-
9-ethylcarbazole tablets (Sigma-Aldrich). Plates were read using an AID ELISpot
reader according to the manufacturer’s instructions.
In vitro proliferation and differentiation. Splenocytes were labelled with 50 nM
CFSE for 10 min before being washed twice in cold culture medium (RPMI, 10%
FCS, penicillin/streptomycin, sodium pyruvate). Cells were then plated at 2 × 106/
ml in round bottom 96-well plates and stimulated for 96 h with 10 μg/ml of E. coli
lipopolysaccharide (LPS) (Sigma-Aldrich). B-cell proliferation was measured by
quantifying CFSE dilution by ﬂow cytometry. B-cell differentiation was measured
by quantifying the percentage of CD138hiB220lo plasmablasts by ﬂow cytometry.
Statistical analysis of the mouse data. When three groups were compared, the p-
values were determined with the Prism software using the Kruskal–Wallis non-
parametric test (signiﬁcant p-values are indicated on the ﬁgures). When two groups
were compared, the p-values were determined with the Prism software using the
Mann–Whitney unpaired two-tailed non-parametric test (signiﬁcant p-values are
indicated on the ﬁgures by stars; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Non-signiﬁcant p-values are indicated by “n.s”.
Cell sorting for the human repertoire analysis. Peripheral blood mononuclear
cells (PBMCs) were obtained from healthy individuals homozygous for the
FcγRIIB-T232 or FcγRIIB-I232 site, under appropriate ethics approval from the
NIHR Cambridge Bioresource. Inclusion criteria for individuals were people aged
between 44 and 77 years, with no serious co-morbidities, no direct family history of
autoimmune disease, no use of immunosuppressants or steroids and no hospita-
lisation within the last 12 months. Individuals were age and sex matched (18
females and 11 males matched between genotypes). Flow sorting was performed
using CD19-BV785, CD38-BV711, CD3-NC650, CD14-605NC, CD24-PerCP-
Cy5.5, IgD-FITC, CD27-PE-Cy7 (all from BD Bioscience) and Aqua (for live-dead
cell detection, Invitrogen), where ﬂow protocol is outlined in Supplementary Fig. 7.
Inclusion criteria for the SLE cohort. Inclusion criteria for healthy individuals
were people aged between 20 and 77 years, with no serious co-morbidities, no
direct family history of autoimmune disease, no use of immunosuppressants or
steroids, and no hospitalisation within the last 12 months.
The SLE cohort comprised patients attending or referred to the Addenbrooke’s
Hospital specialist vasculitis unit between July 2004 and June 2016 who met at least
four American College of Rheumatology SLE criteria66, presenting with active
disease (deﬁned as a) new BILAG score of A or B in any system (including switch
from C to A or D to B), b) physician assessment of active disease, and c) a
requirement for an increase of immunosuppressive treatment (excluding isolated
increase/commencement of prednisolone at a dose ≤25 mg). After treatment with
an immunosuppressant, patients were followed up monthly. Disease monitoring
was undertaken with serial British Isles Lupus Assessment Group disease scoring
(BILAG, a major international SLE activity scoring system)67 and serum anti-
nuclear antibody status.
Ethical approval for this study was obtained from the Cambridge Local
Research Ethics Committee (reference numbers 04/023, 08/H0306/21, 08/H0308/
176) and Eastern NHS Multi Research Ethics Committee (07/MRE05/44), with
informed consent obtained from all subjects enrolled.
Reverse transcription and ampliﬁcation. Repertoire analysis was performed as
described52. Brieﬂy, RNA extraction was performed using RNeasy Micro Kit
(Qiagen) according to the manufacturer’s protocol. Reverse transcription (RT) was
performed in a 23 -μL reaction with SuperScript®III (Thermo Fisher), RNA tem-
plate, 12 μM reverse primer, nuclease-free water and incubated for 5 min at 70 °C.
This mixture was immediately transferred to ice for 1 min, and the RT mix 2 (4 μL
5x FS buffer, 1 μL DTT (0.1 M), 1 μL dNTP (10 mM), 1 μL SuperscriptIII) was
added and incubated at 50 °C for 60 min followed by 15 min inactivation at 70 °C.
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cDNA was cleaned-up with Agencourt AMPure XP beads and PCR ampliﬁed with
V-gene multiplex primer mix (10 μM each forward primer) and 3′ universal reverse
primer (10 μM) using KAPA protocol and the thermal cycling conditions: 1 cycle
(95 °C—5 min); 5 cycles (98 °C—5 s; 72 °C—2 min); 5 cycles (65 °C—10 s, 72 °C—
2 min); 25 cycles (98 °C—20 s, 60 °C— 1 min, 72 °C—2 min) and 1 step (72 °C—10
min). Primers are provided in Supplementary Table 3.
IgH sequencing and analysis. MiSeq libraries were prepared using Illumina
protocols and sequenced using 300 bp paired-ended MiSeq (Illumina). Raw MiSeq
reads were ﬁltered for base quality (median Phred score > 32) using QUASR
(http://sourceforge.net/projects/quasr/)68. MiSeq forward and reverse reads were
merged together if they contained identical overlapping regions of >50 bp, or
otherwise discarded. Universal barcoded regions were identiﬁed in reads and
orientated to read from V-primer to constant region primer. The barcoded region
within each primer was identiﬁed and checked for conserved bases (i.e. the T’s in
NNNNTNNNNTNNNNT). Primers and constant regions were trimmed from
each sequence, and sequences were retained only if there was >80% sequence
certainty between all sequences obtained with the same barcode, otherwise dis-
carded. The constant region allele with highest sequence similarity was identiﬁed
by 10-mer matching to the reference constant region genes from the IMGT
database69, and sequences were trimmed to give only the region of the sequence
corresponding to the variable (V–D–J) regions. Isotype usage information for each
IgH was retained throughout the analysis hereafter. Sequences without complete
reading frames and non-immunoglobulin sequences were removed and only reads
with signiﬁcant similarity to reference IgHV and J genes from the IMGT database
were retained using BLAST70. IgH gene usages and sequence annotation was
performed in IMGT V-QUEST, where repertoire differences were performed by
custom scripts in python, and statistics were performed in R using Wilcoxon tests
for signiﬁcance (non-parametric test of differences between distributions).
Software and algorithms for repertoire analysis. The following software and
algorithms were used: QUASR68 (http://sourceforge.net/projects/quasr/), BLAST70
(https://blast.ncbi.nlm.nih.gov/Blast.cgi), IMGT V-QUEST69 (http://www.imgt.
org/HighV-QUEST/), Immune_receptor_NETWORK-GENERATION71 (https://
github.com/rbr1/Immune_receptor_NETWORK-GENERATION) and R version
3.3.3 (2017-03-06, https://www.r-project.org).
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
A reporting summary for this article is available as a Supplementary Information ﬁle. The
source data underlying Figs. 1 to 6 and Supplementary Figs. 1–6 are available as a Source
Data ﬁle. EGA accession numbers for sequencing data are provided in Supplementary
Table 4 (https://www.ebi.ac.uk/ega/). All other relevant data are available from the
authors upon reasonable requests.
Code availability
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